The Lancet Haematology
Издатель: Elsevier · ISSN 2352-3026 · 28 статей
- Personalising AML treatment: beyond age and fitness
- Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia
- Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply
- Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)
- Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
- Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
- Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial
- High time for risk-adapted treatment in mantle cell lymphoma
- At the heart of unmet need: TP53 myeloid neoplasms
- Redefining plasma cell leukaemia
- When inflammation conceals malignancy in the urinary bladder
- Thalassaemia revisited: whose progress?
- Bridging the thalassaemia divide in south and southeast Asia
- α-thalassaemia: an overlooked disease entering a new era
- Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa
- Rethinking anti-BCMA T-cell engager design
- Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding?
- Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding? – Authors’ reply
- Should plasma cell leukaemia be classified as multiple myeloma?
- Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial
- Phenotype, treatment, and determinants of prognosis in Erdheim–Chester disease: an international, retrospective, cohort study
- Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial
- MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study
- The expanding therapeutic landscape of β-thalassaemia
- Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration
- Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia
- Rethinking the possibilities of adult ring sideroblastic anaemia
- Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial